Biotech entity
All 2 tracked stories fall under one category: pharma. BioLife Solutions is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 15.5 original sources each against 3.9 for the same window.
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. BioLife Solutions is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 15.5 original sources each against 3.9 for the same window. At 6, the average consequence score sits above the same-window beat average of 5.9. We currently track 2 Biotech stories that mention Indivior, published between February 26, 2026 and February 27, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 35 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Indivior. Shared-story counts are live from our verified record — not editorial picks.
The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Indivior is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
